Comprehensive EBV Antibody Panel
Epstein-Barr Virus (EBV), also known as Human Herpesvirus 4 (HHV-4), is one of the most ubiquitous human viruses globally. It is not only the primary causative agent of infectious mononucleosis (IM), but its latent infection mechanisms are also closely linked to the development of various malignancies (such as Burkitt lymphoma and nasopharyngeal carcinoma) and autoimmune diseases.
In research endeavors spanning in vitro cell model validation, experimental animal tracking, and population-based epidemiological surveys, accurately determining the EBV infection stage of the subject (e.g., naïve, recent/acute, past infection, or latent reactivation) is a prerequisite for downstream mechanistic studies. Because a single antibody marker often fails to provide a complete picture of the infection phase, multiplex testing of specific antibodies against different EBV structural proteins (i.e., an EBV antibody panel) is internationally recognized as the most reliable research tool for evaluating EBV infection status.
Our Services
We provide a high-standard, comprehensive EBV serological research panel. A single assay covers the three core immunological biomarkers, providing multi-dimensional data support for your research projects:
- EBV VCA Antibody (IgM):
- Target: IgM antibodies against the Viral Capsid Antigen (VCA).
- Research Value: VCA-IgM typically appears very rapidly in the earliest stages of an EBV infection and gradually disappears over several weeks to months. It serves as the hallmark early indicator for identifying a recent or acute EBV infection.
- EBV VCA Antibody (IgG):
- Target: IgG antibodies against the Viral Capsid Antigen.
- Research Value: VCA-IgG emerges during the acute phase and is maintained at a certain titer level for life within the host. It is primarily used to evaluate whether the host has ever been exposed to EBV, serving as a critical reference for assessing baseline immune status.
- EBV Nuclear Antigen (EBNA) Antibody (IgG):
- Target: IgG antibodies against the Epstein-Barr Virus Nuclear Antigen (EBNA, usually referring to EBNA-1).
- Research Value: Unlike VCA antibodies, EBNA-IgG typically does not appear until months after the initial infection (during the convalescent or latent phase) and persists for life. The combination of a positive VCA-IgG and a positive EBNA-IgG is the "gold standard" for confirming that a subject is in the past/latent infection stage.
What Does The Test Result Mean?
In research data analysis, different combinations of positive and negative EBV antibody targets represent distinct biological contexts. The table below illustrates the most classic serological patterns and their corresponding infection phase interpretations:
| VCA Antibody (IgM) | VCA Antibody (IgG) | EBNA Antibody (IgG) | Research Interpretation & Infection Phase |
| Negative (-) | Negative (-) | Negative (-) | Naïve (Unexposed): The host model has never been infected with EBV and is in a state of complete immunological susceptibility. |
| Positive (+) | Negative (-) or Positive (+) | Negative (-) | Early/Acute Exposure (Primary Infection): Indicates that the host is in the very early stages of an EBV infection. |
| Negative (-) | Positive (+) | Negative (-) | Transitional Phase / Recent Infection: Suggests the infection occurred some time ago; early IgM has decayed below the detection threshold, but latent-phase EBNA-IgG has not yet been produced in massive quantities. |
| Negative (-) | Positive (+) | Positive (+) | Past / Latent Infection: Indicates the host was previously infected with EBV and has now entered long-term immune memory and viral latency maintenance (this is the most common steady-state serological pattern in adult populations). |
(Note: Atypical antibody combinations may appear in rare immunodeficient models or specific pathological states, requiring deep analysis in conjunction with the specific research context.)
Sample Requirements
To ensure the precise capture of immunological signals and the reproducibility of your data, please prepare your research samples according to the following guidelines:
- Sample Type: Serum.
- Preferred Volume: We highly recommend submitting 1.0 mL of serum to accommodate multi-target retesting and sample retention for quality control.
- Minimum Volume: For precious or micro-volume experimental models, the absolute minimum acceptable volume for this panel is 0.8 mL.
On the research path to deciphering the complex pathogenic mechanisms and latency characteristics of the Epstein-Barr Virus, rigorous and reliable serological staging data is indispensable. Contact our expert team today to get your customized EBV comprehensive testing plan, and let us provide the solid data foundation for your next scientific breakthrough!
